ENTA
Enanta Pharmaceuticals, Inc. NASDAQ Listed Mar 21, 2013$13.77
+3.22%
vs $13.34
Mkt Cap $293.8M
52w Low $6.49
70.3% of range
52w High $16.85
50d MA $13.05
200d MA $13.36
P/E (TTM)
-5.0x
EV/EBITDA
—
P/B
4.5x
Debt/Equity
3.1x
ROE
-56.5%
P/FCF
-9.1x
RSI (14)
58.60
ATR (14)
$0.59
Beta
1.00
50d MA
$13.05
200d MA
$13.36
Avg Volume
209.5K
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
500 Arsenal Street · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | AMC | -0.54 | -0.42 | +22.2% | 13.83 | +9.3% | +2.2% | +0.8% | -2.9% | +0.1% | +0.1% | — |
| Nov 17, 2025 | AMC | -1.13 | -0.87 | +23.0% | 12.82 | -4.7% | -3.6% | -1.9% | +0.0% | +4.9% | +7.2% | — |
| Aug 11, 2025 | AMC | -1.25 | -0.85 | +32.0% | 6.49 | +1.5% | +5.7% | +10.5% | +2.1% | +3.4% | +2.1% | — |
| May 12, 2025 | AMC | -1.04 | -1.06 | -1.9% | 5.55 | -0.7% | -5.8% | -1.0% | +3.7% | +7.1% | +3.7% | — |
| Feb 10, 2025 | AMC | -1.16 | -1.05 | +9.5% | 4.90 | +7.1% | +14.1% | +4.8% | +28.0% | -4.8% | +4.9% | — |
| Nov 25, 2024 | AMC | -1.16 | -1.36 | -17.2% | 9.01 | -2.3% | -5.0% | +3.2% | -2.6% | -0.3% | +2.2% | — |
| Aug 5, 2024 | AMC | -1.49 | -1.07 | +28.2% | 12.85 | -2.7% | +1.2% | -4.8% | +9.1% | -6.7% | -1.9% | — |
| May 6, 2024 | AMC | -1.26 | -1.47 | -16.7% | 14.60 | -20.5% | -10.3% | -2.6% | +1.3% | -2.2% | +2.1% | — |
| Feb 7, 2024 | AMC | -1.18 | -1.58 | -33.9% | 12.26 | -3.4% | +0.8% | -0.2% | -0.1% | -0.2% | +7.3% | — |
| Nov 20, 2023 | AMC | -2.11 | -1.33 | +37.0% | 8.94 | +5.9% | +11.5% | -9.8% | +10.6% | -3.6% | +1.4% | — |
| Aug 7, 2023 | AMC | -2.38 | -1.86 | +21.8% | 19.34 | -7.9% | -4.2% | -9.8% | -1.8% | -3.1% | -0.8% | — |
| May 8, 2023 | AMC | -1.91 | -1.79 | +6.3% | 34.33 | -30.1% | -25.7% | +3.9% | -3.7% | -0.7% | +2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.83 | $15.12 | +9.3% | +2.2% | +0.8% | -2.9% | +0.1% | +0.1% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.44 | $13.50 | +0.4% | -2.5% | -1.5% | +1.7% | +5.4% | -3.5% |
| Oct 1 | Jefferies | Upgrade | Hold → Buy | — | $11.97 | $10.23 | -14.5% | -11.4% | -2.6% | +0.0% | +9.9% | -2.4% |
| Sep 30 | WestPark Capital | Maintains | Buy → Buy | — | $15.16 | $14.99 | -1.1% | -21.0% | -11.4% | -2.6% | +0.0% | +9.9% |
| Sep 15 | Evercore ISI | Maintains | Outperform → Outperform | — | $8.28 | $8.32 | +0.5% | -9.9% | -0.1% | +1.2% | +4.0% | -2.6% |
| Aug 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.49 | $6.59 | +1.5% | +5.7% | +10.5% | +2.1% | +3.4% | +2.1% |
| Jun 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.29 | $6.44 | +2.4% | +14.3% | -1.1% | +1.4% | +3.6% | +0.4% |
| May 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.23 | $5.21 | -0.4% | -1.0% | +3.7% | +7.1% | +3.7% | +1.8% |
| Feb 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.90 | $5.25 | +7.1% | +14.1% | +4.8% | +28.0% | -4.8% | +4.9% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.90 | $5.25 | +7.1% | +14.1% | +4.8% | +28.0% | -4.8% | +4.9% |
| Dec 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.37 | $6.08 | -4.6% | -4.2% | -1.6% | +0.2% | -2.7% | -1.7% |
| Nov 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.01 | $8.80 | -2.3% | -5.0% | +3.2% | -2.6% | -0.3% | +2.2% |
| Nov 26 | Baird | Maintains | Outperform → Outperform | — | $9.01 | $8.80 | -2.3% | -5.0% | +3.2% | -2.6% | -0.3% | +2.2% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.71 | $10.71 | +0.0% | -0.7% | +3.9% | +2.4% | +3.2% | +3.7% |
| Oct 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $11.00 | $10.96 | -0.4% | -2.6% | -0.7% | +3.9% | +2.4% | +3.2% |
| Sep 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $10.47 | $10.50 | +0.3% | -4.0% | +3.1% | +5.6% | +2.8% | -0.5% |
| Aug 6 | JP Morgan | Maintains | Underweight → Underweight | — | $12.85 | $12.50 | -2.7% | +1.2% | -4.8% | +9.1% | -6.7% | -1.9% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.85 | $12.50 | -2.7% | +1.2% | -4.8% | +9.1% | -6.7% | -1.9% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.60 | $11.60 | -20.5% | -10.3% | -2.6% | +1.3% | -2.2% | +2.1% |
| May 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.60 | $11.60 | -20.5% | -10.3% | -2.6% | +1.3% | -2.2% | +2.1% |
| Feb 8 | JP Morgan | Maintains | Underweight → Underweight | — | $12.26 | $11.84 | -3.4% | +0.8% | -0.2% | -0.1% | -0.2% | +7.3% |
| Nov 22 | Oppenheimer | Maintains | Perform → Perform | — | $9.97 | $9.99 | +0.2% | -9.8% | +10.6% | -3.6% | +1.4% | +2.2% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.94 | $9.47 | +5.9% | +11.5% | -9.8% | +10.6% | -3.6% | +1.4% |
| Nov 21 | JMP Securities | Maintains | Outperform → Outperform | — | $8.94 | $9.47 | +5.9% | +11.5% | -9.8% | +10.6% | -3.6% | +1.4% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.20 | $9.08 | -1.3% | -2.7% | +0.3% | -2.2% | -3.9% | -1.1% |
| Oct 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $11.17 | $11.05 | -1.1% | -6.1% | +2.8% | -6.7% | -0.7% | -1.5% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.63 | $12.67 | +0.3% | +1.7% | -1.7% | -6.4% | +0.7% | -6.7% |
| Aug 9 | Oppenheimer | Maintains | Perform → Perform | — | $18.52 | $17.35 | -6.3% | -9.8% | -1.8% | -3.1% | -0.8% | +0.6% |
| Aug 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $19.34 | $17.82 | -7.9% | -4.2% | -9.8% | -1.8% | -3.1% | -0.8% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.34 | $17.82 | -7.9% | -4.2% | -9.8% | -1.8% | -3.1% | -0.8% |
| Aug 8 | Jefferies | Downgrade | Buy → Hold | — | $19.34 | $17.82 | -7.9% | -4.2% | -9.8% | -1.8% | -3.1% | -0.8% |
| Aug 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $19.34 | $17.82 | -7.9% | -4.2% | -9.8% | -1.8% | -3.1% | -0.8% |
| May 11 | Oppenheimer | Maintains | Perform → Perform | — | $26.51 | $25.88 | -2.4% | -3.7% | -0.7% | +2.1% | -4.8% | +3.5% |
| May 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $34.33 | $24.00 | -30.1% | -25.7% | +3.9% | -3.7% | -0.7% | +2.1% |
| May 9 | JMP Securities | Maintains | Outperform → Outperform | — | $34.33 | $24.00 | -30.1% | -25.7% | +3.9% | -3.7% | -0.7% | +2.1% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.33 | $24.00 | -30.1% | -25.7% | +3.9% | -3.7% | -0.7% | +2.1% |
| Mar 22 | RBC Capital | Maintains | Sector Perform → Perform | — | $40.89 | $40.90 | +0.0% | -2.9% | -0.2% | +1.2% | -0.6% | -2.5% |
| Feb 9 | SVB Leerink | Maintains | Market Perform → Perform | — | $52.66 | $53.18 | +1.0% | +0.8% | -0.0% | -3.7% | -2.6% | +0.8% |
| Feb 8 | JP Morgan | Maintains | Neutral → Neutral | — | $54.59 | $62.06 | +13.7% | -3.5% | +0.8% | -0.0% | -3.7% | -2.6% |
| Feb 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $54.59 | $62.06 | +13.7% | -3.5% | +0.8% | -0.0% | -3.7% | -2.6% |
| Jan 27 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $51.51 | $51.34 | -0.3% | +1.0% | -2.1% | +4.8% | -2.8% | +1.6% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.96 | $42.81 | +2.0% | -0.6% | +2.5% | +2.5% | +1.5% | -1.5% |
| Nov 22 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $46.40 | $41.94 | -9.6% | -2.1% | -1.0% | -7.6% | -1.1% | +2.0% |
| Aug 10 | Oppenheimer | Maintains | Perform → Perform | — | $68.27 | $68.37 | +0.1% | -0.6% | -2.1% | +2.3% | +3.6% | -0.7% |
| Aug 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $71.27 | $71.84 | +0.8% | -4.2% | -0.6% | -2.1% | +2.3% | +3.6% |
| Aug 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $71.27 | $71.84 | +0.8% | -4.2% | -0.6% | -2.1% | +2.3% | +3.6% |
| Aug 1 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $55.15 | $55.05 | -0.2% | +8.2% | +0.6% | +7.5% | +5.4% | +4.2% |
| Aug 1 | Oppenheimer | Maintains | Perform → Perform | — | $55.15 | $55.05 | -0.2% | +8.2% | +0.6% | +7.5% | +5.4% | +4.2% |
| Jul 6 | Evercore ISI | Upgrade | In Line → Outperform | — | $52.68 | $54.51 | +3.5% | -2.5% | +1.1% | +1.7% | -6.0% | +2.9% |
| Jul 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $47.27 | $47.64 | +0.8% | +5.0% | +6.1% | -2.5% | +1.1% | +1.7% |
No insider trades available.
8-K
Enanta Pharmaceuticals, Inc. -- 8-K Filing
Jul 2
8-K
Enanta Pharmaceuticals, Inc. -- 8-K Filing
Jun 23
8-K · 7.01
! Medium
Enanta Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 18
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This 8-K filing appears to be a technical SEC submission for Entasis Therapeutics (ENTA); without disclosed material events or substantive announcements, investors should await actual business updates affecting the biotech company's pipeline or financial position.
Mar 26
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
ENTA reserved 1.6M shares for executive compensation, signaling potential dilution to shareholders and indicating the company is increasing equity incentives, which could pressure stock price near-term.
Mar 12
8-K
Enanta Pharmaceuticals, Inc -- 8-K Filing
Enanta Pharmaceuticals is advancing its RSV treatment portfolio toward Phase 3 trials while expanding immunology efforts with a new oral MRGPRX2 inhibitor program, demonstrating pipeline momentum.
Feb 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 3,784,055 | $48M | New | Mar 2026 |
| 2 | Farallon Capital Management Llc | 2,871,862 | $36M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,178,049 | $15M | New | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 948,904 | $12M | New | Mar 2026 |
| 5 | Millennium Management | 882,097 | $11M | Added | Mar 2026 |
| 6 | Acadian Asset Management Llc | 880,023 | $11M | Reduced | Mar 2026 |
| 7 | Morgan Stanley | 679,836 | $11M | Added | Dec 2025 |
| 8 | Renaissance Technologies Llc | 665,258 | $8M | Added | Mar 2026 |
| 9 | Aqr Capital Management Llc | 313,157 | $4M | Added | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 267,364 | $3M | Reduced | Mar 2026 |
| 11 | Citadel Advisors Llc | 262,533 | $3M | Added | Mar 2026 |
| 12 | Northern Trust Corp | 240,968 | $3M | Added | Mar 2026 |
| 13 | Marshall Wace, Llp | 210,070 | $3M | Reduced | Mar 2026 |
| 14 | Invesco Ltd. | 182,002 | $2M | Reduced | Mar 2026 |
| 15 | Connor, Clark & Lunn Investment Management Ltd. | 103,903 | $2M | Added | Dec 2025 |
| 16 | Qube Research & Technologies Ltd | 116,961 | $1M | Added | Mar 2026 |
| 17 | Sei Investments Co | 109,077 | $1M | Added | Mar 2026 |
| 18 | Jpmorgan Chase & Co | 103,059 | $1M | Reduced | Mar 2026 |
| 19 | Opaleye Management Inc. | 75,000 | $1M | New | Dec 2025 |
| 20 | Panagora Asset Management Inc | 89,599 | $1M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$293.8M
Enterprise Value
$217.4M
P/E (TTM)
-5.03x
Forward P/E
—
PEG Ratio
0.10x
P/B
4.54x
P/S
4.24x
P/FCF
-9.13x
EV/EBITDA
—
Shares Out
21.3M
Financials (TTM)
Revenue
$69.2M
Net Income
-$62.0M
EBITDA
-$46.6M
Free Cash Flow
-$32.2M
Op Cash Flow
-$19.3M
EPS Basic
$-3.84
EPS Diluted
$-2.74
EPS Forward
$-2.47
Gross Margin
98.2%
Op Margin
-87.2%
Net Margin
-89.6%
Balance Sheet
Total Assets
$280.7M
Total Liab.
$216.0M
Total Equity
$64.7M
Cash
$188.9M
LT Debt
$112.4M
Book Value/Sh
$3.03
Debt/Equity
3.11x
Current Ratio
4.21
Quick Ratio
4.21
Returns & Growth
ROE
-56.5%
ROA
-21.7%
ROIC
-31.4%
Rev Growth YoY
-3.4%
EPS Growth YoY
+29.9%
Price Returns
2W
+3.0%
1M
-6.5%
3M
-11.6%
6M
-1.3%
12M
+90.8%
Technicals
52W High
$16.85
52W Low
$6.49
50d MA
$13.05
200d MA
$13.36
RSI (14)
58.60
ATR (14)
$0.59
Beta
1.00
Avg Volume
210K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$48.20
High
$87.00
Low
$20.00
Median
$54.00
Data updated apr 25, 2026 7:15am
· Source: financialmodelingprep.com